Medical treatment of brain tumours, particularly glioma, with an emphasis on novel drug evaluation for glioblastoma
Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
J Clin Oncol. 2019 Jan 04;:JCO1800474
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Oncologist. 2018 Sep 28;:
PLoS One. 2018;13(8):e0202860
Significance of treatment response when managing patients with primary central nervous system lymphoma.
Leuk Lymphoma. 2018 Jul 03;:1-9
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo.
Neuro Oncol. 2018 Apr 20;:
Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Neuro Oncol. 2018 Apr 05;:
Neuro Oncol. 2018 Mar 28;:
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Eur J Cancer. 2018 Mar 20;94:168-178
Oculoleptomeningeal amyloidosis secondary to the rare Transthyretin c.381T>G (p.Ile127Met) mutation.
World Neurosurg. 2017 Dec 22;:
Curr Oncol. 2017 Dec;24(6):374-382
Associate Professor, Department of Medicine, University of Toronto
Medical Director, Gerry and Nancy Pencer Brain Tumour Centre
Kirchmann Family Chair in Neurooncology Research, Princess Margaret Hospital